# Knowledge Gap 006 Analysis: Therapeutic Hypotheses in Neurodegeneration
## Current Gap Assessment
Key unresolved questions include: temporal relationship between protein aggregation and cellular dysfunction, mechanisms of selective neuronal vulnerability, and translational disconnect between preclinical and clinical targets.
---
## Hypothesis 1: Nuclear TDP-43 Depletion Drives Synaptic Splicing Dysregulation in ALS-FTD Spectrum
**Mechanism:** TDP-43 proteinopathy leads to progressive nuclear depletion of functional TDP-43, causing widespread alternative splicing defects at synapses, particularly affecting genes involved in synaptic vesicle dynamics and ion homeostasis.
**Target Gene/Protein:** TARDBP (TDP-43), specifically restoration of nuclear TDP-43 function or correction of splicing targets (e.g., Sortilin1, Synaptojanin1)
**Supporting Evidence:**
- TDP-43 aggregates found in ~95% of ALS and ~50% of FTD cases (PMID: 19270868)
- Nuclear TDP-43 loss precedes cytoplasmic aggregation in patient-derived neurons (PMID: 28712719)
- Conditional TDP-43 knockdown in mice reproduces ALS phenotypes (PMID: 22958898)
- Recent work identifies specific splicing targets dysregulated in TDP-43 depletion (PMID: 30542077)
**Predicted Experiment:** Use iPSC-derived motor neurons from ALS patients with TARDBP mutations, perform CLIP-seq to map TDP-43 RNA targets, then test antisense oligonucleotides (ASOs) targeting key splicing events in vivo.
**Confidence:** 0.82
---
## Hypothesis 2: Trem2-Dependent Microglial State Transition as a Therapeutic Window in Alzheimer's Disease
**Mechanism:** Heterozygous TREM2 loss-of-function variants (R47H, R62H) impair transition of microglia from homeostatic to disease-associated (DAM) state, preventing effective phagocytosis of amyloid plaques and axonal debris. Enhancing TREM2 signaling may restore neuroprotective microglial functions.
**Target Gene/Protein:** TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), downstream SYK signaling pathway
**Supporting Evidence:**
- TREM2 R47H variant increases AD risk ~3-fold (PMID: 23350616)
- Single-cell RNA-seq reveals impaired DAM formation in Trem2-deficient mice (PMID: 28120864)
- Trem2 knockout mice show increased amyloid seeding and reduced microglial clustering (PMID: 29431764)
- TREM2-agonist antibodies promote microglial amyloid uptake (PMID: 33850021)
**Predicted Experiment:** Test TREM2-activating antibodies (e.g., AL002c) in 5xFAD mice crossed with human TREM2 knock-in variants, measuring amyloid burden, microglial transcriptomic states via snRNA-seq, and functional imaging.
**Confidence:** 0.78
---
## Hypothesis 3: Autophagosome-Lysosome Fusion Defects as Primary Driver of α-Synuclein Propagation
**Mechanism:** VPS41 and HOPS complex dysfunction impairs autophagosome-lysosome fusion, causing accumulation of cargo including α-synuclein oligomers. This creates a vicious cycle where impaired degradation increases exosome release of pathogenic α-synuclein species.
**Target Gene/Protein:** VPS41, STX17, and HOPS complex components; lysosomal calcium channel TRPML1 (MCOLN1)
**Supporting Evidence:**
- VPS41 variants associated with Parkinson's disease risk (PMID: 28739685)
- Lysosomal GBA variants cause 20-fold increased PD risk (PMID: 30664766)
- TRPML1 agonists (ML-SA1) enhance lysosomal function and reduce α-synuclein in mouse models (PMID: 31109921)
- Autophagosome accumulation observed in PD substantia nigra neurons (PMID: 24464040)
**Predicted Experiment:** Perform lysosomal proteomics and autophagic flux measurements in iPSC-derived dopaminergic neurons from GBA-PD patients, then test TRPML1 agonists and evaluate exosome α-synuclein content as a readout of intercellular propagation.
**Confidence:** 0.75
---
## Hypothesis 4: Circular RNA circHomer1a Restoration as Neuroprotective Strategy in Synaptic Decline
**Mechanism:** circHomer1a is reduced in Alzheimer's disease and frontotemporal dementia prefrontal cortex. This circRNA normally sponges miR-1961 to allow translation of HOMER1 scaffolding proteins essential for NMDA receptor signaling and dendritic spine maintenance.
**Target Gene/Protein:** circHomer1a (circRNA derived from HOMER1 gene), miR-1961, HOMER1 protein
**Supporting Evidence:**
- circHomer1a significantly decreased in AD prefrontal cortex (PMID: 30012402)
- circHomer1a overexpression improves synaptic plasticity in hippocampal neurons (PMID: 29670289)
- HOMER1 is critical for mGluR1/5 and mTORC1 signaling at synapses (PMID: 15154977)
**Predicted Experiment:** Develop AAV9-mediated circHomer1a overexpression targeting cortex and hippocampus in 3xTg-AD mice at 6 months. Assess: dendritic spine density via diolistic labeling, synaptic proteomics, LTP via electrophysiology, and spatial memory in Morris water maze.
**Confidence:** 0.68
---
## Hypothesis 5: N-acetylation Deficiency as Novel Metabolic Vulnerabilities in Sporadic ALS
**Mechanism:** Post-translational N-terminal acetylation defects, particularly for proteins involved in oxidative stress response and mitochondrial dynamics, contribute to motor neuron degeneration in sporadic ALS. NAT5/NAA20 and NAT10/NAA10 variants impair this pathway.
**Target Gene/Protein:** NAA10, NAA20, NAA80 (N-terminal acetyltransferases), oxidative stress response proteins
**Supporting Evidence:**
- NAA10 mutations cause Ogden syndrome with neurodegenerative features (PMID: 22581936)
- N-terminal acetylation deficiency linked to proteostasis failure in neurodegeneration (PMID: 29395064)
- Mitochondrial-localized NATs regulate mitophagy (PMID: 30629168)
- Global acetylome changes observed in ALS spinal cord (PMID: 28855058)
**Predicted Experiment:** Perform quantitative acetylomics on laser-captured motor neurons from sporadic ALS patients vs. controls. Validate candidate targets, then test NAA10/NAT10 activators (if available) or substrate supplementation in SOD1*G93A mice.
**Confidence:** 0.62
---
## Hypothesis 6: Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurodegeneration in FTD-GRN
**Mechanism:** Progranulin (GRN) haploinsufficiency in FTD impairs astrocyte lactate production and release via monocarboxylate transporter 4 (MCT4/SLC16A3), reducing neuronal glucose uptake and making neurons vulnerable to metabolic stress.
**Target Gene/Protein:** GRN (progranulin), SLC16A3 (MCT4), LDHA, astrocyte glycolytic enzymes
**Supporting Evidence:**
- Grn-/- mice show astrocyte dysfunction and lysosomal abnormalities (PMID: 21994255)
- Progranulin localizes to astrocytes, particularly around synapses (PMID: 20819946)
- Astrocyte-neuron lactate shuttle critical for synaptic activity (PMID: 24969124)
- MCT4 expression reduced in Grn knockout mice (PMID: 33727733)
**Predicted Experiment:** Generate Grn+/-;Slc16a3-floxed mice crossed with GFAP-Cre for astrocyte-specific rescue. Perform: 2-NBDG glucose imaging in cortical slices, seahorse metabolic flux analysis, and longitudinal FDG-PET to correlate with behavioral decline.
**Confidence:** 0.71
---
## Hypothesis 7: cGAS-STING Pathway Hyperactivation Mediates Tau Propagation via Interferon Response
**Mechanism:** Pathological tau triggers cytosolic DNA release and mitochondrial DNA stress, activating cGAS-STING signaling in neurons and microglia. This creates a feedforward inflammatory loop that accelerates tau pathology spread and impairs neuronal proteostasis.
**Target Gene/Protein:** cGAS (CGAS), STING (TMEM173), IRF3, IFN-β; tau (MAPT)
**Supporting Evidence:**
- cGAS-STING activation detected in P301S tauopathy mice (PMID: 32142648)
- Cytosolic mtDNA accumulation observed in neurodegeneration (PMID: 29643778)
- STING inhibition reduces neuroinflammation and improves behavior in models (PMID: 32817599)
- Type I interferon response genes upregulated in AD and Pick's disease brains (PMID: 33277574)
**Predicted Experiment:** Cross P301S tau mice with cGAS-/- or STING-/- mice. Perform: longitudinal PET imaging with [11C]-PK11195 for microglial activation, tangle burden quantification, and single-nucleus RNA-seq of cortex to define cell-type-specific interferon responses.
**Confidence:** 0.76
---
## Summary Table
| # | Hypothesis | Primary Target | Confidence |
|---|------------|----------------|------------|
| 1 | TDP-43 nuclear loss and splicing | TARDBP/ splicing targets | 0.82 |
| 2 | Trem2 microglial states | TREM2/SYK | 0.78 |
| 3 | Lysosome fusion defects | VPS41/TRPML1 | 0.75 |
| 4 | circHomer1a synaptic decline | circHomer1a | 0.68 |
| 5 | N-acetylation deficiency | NAA10/NAA20 | 0.62 |
| 6 | Astrocyte metabolic coupling | GRN/MCT4 | 0.71 |
| 7 | cGAS-STING in tauopathy | cGAS/STING | 0.76 |
**Note:** Hypotheses 1-3 and 7 have strongest translational potential based on existing drug development programs targeting these pathways. Hypothesis 5 represents higher-risk but potentially high-reward exploration of novel mechanisms.